Perpectives in Urology: Point-Counterpoint 2017

An Overview of MRI Guided Biopsies for Prostate Cancer

Robert Abouassaly, MD, argues that the DECIPHER marker is not an ideal test for predicting patient’s response to chemotherapy. He cites the inconclusiveness of trials and research and the cost inefficiency of this biomarker. Also, he explains that the DECIPHER test’s classification system is based on RNA expression profiles, and not meant for therapeutic guidance. This is a counter argument to Alan H. Bryce’s lecture, “The DECIPHER Marker Can Predict Chemotherapy.” 

Read More

HIFU: Ready for Prime Time

David C. Beyer, MD, argues that there is enough research from randomized trials and clinical studies for the urological community to consider high intensity focused ultrasound (HIFU) as a standard of care for treating prostate cancer patients.

Read More

HIFU is not Ready for Prime Time

Erik P. Castle, MD, argues that using high intensity focused ultrasound (HIFU) to treat prostate cancer, as the technology stands today, results in too many negative quality of life outcomes for patients. Therefore, HIFU is not ready to be a standard of care in urological practices.

Read More

Join the GRU Community

- Why Join? -